NLGIA
VRTX icon

Nippon Life Global Investors Americas’s Vertex Pharmaceuticals VRTX Stock Holding History

Nippon Life Global Investors Americas’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Buy
38,230
+35,730
+1,429% +$15.8M 0.76% 37
2026
Q1 		$1.12M Buy
2,500
+250
+11% +$117K 0.05% 86
2025
Q4 		$1.02M Sell
2,250
-580
-20% -$250K 0.04% 86
2025
Q3 		$1.11M Buy
+2,830
New +$1.18M 0.05% 89

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nippon Life Global Investors Americas's VRTX Position: Q2 2026 in Review

Nippon Life Global Investors Americas increased its Vertex Pharmaceuticals (VRTX) stake by 1,429% in Q2 2026, buying an estimated $15.8M and bringing the position to 38,230 shares worth $19M. The position accounts for 0.76% of the portfolio, ranked #37.

Nippon Life Global Investors Americas first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 1,190 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Nippon Life Global Investors Americas held 38,230 shares of Vertex Pharmaceuticals worth $19M as of Q2 2026.
  • Nippon Life Global Investors Americas bought 35,730 Vertex Pharmaceuticals shares in Q2 2026, an estimated $15.8M.
  • Vertex Pharmaceuticals made up 0.76% of Nippon Life Global Investors Americas's portfolio in Q2 2026, its #37 holding.
  • Nippon Life Global Investors Americas first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 1,190 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nippon Life Global Investors Americas's 13F filing for Q2 2026, filed 6 Aug 2026.